MedTrace Logo

Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers

NCT03844217 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-08-08

No results posted yet for this study

Summary

This study investigates stimulation of the posterior pituitary gland by oral Macimorelin (a ghrelin receptor Agonist) to be a novel diagnostic test in the polyuria-polydipsia syndrome.

Conditions

  • Polyuria-polydipsia Syndrome

Interventions

DRUG

Macimorelin 0.5mg/kg body weight

oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin

DRUG

Macimorelin 0.75mg/kg body weight

oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Mirjam Christ-Crain, Prof. Dr. MD · Endocrinology, Diabetes and Metabolism, University Hospital Basel

Study Design

Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-07
Primary Completion
2019-07-16
Completion
2019-07-16

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03844217 on ClinicalTrials.gov